Nothing Special   »   [go: up one dir, main page]

IN2014MN02089A - - Google Patents

Info

Publication number
IN2014MN02089A
IN2014MN02089A IN2089MUN2014A IN2014MN02089A IN 2014MN02089 A IN2014MN02089 A IN 2014MN02089A IN 2089MUN2014 A IN2089MUN2014 A IN 2089MUN2014A IN 2014MN02089 A IN2014MN02089 A IN 2014MN02089A
Authority
IN
India
Prior art keywords
subject
blood transfusion
blood
efficacy
administering
Prior art date
Application number
Inventor
Seetharama A Acharya
Marcos Intaglietta
Original Assignee
Einstein Coll Med
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Einstein Coll Med, Univ California filed Critical Einstein Coll Med
Publication of IN2014MN02089A publication Critical patent/IN2014MN02089A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A method of improving the efficacy of a blood transfusion into a subject is provided comprising administering a composition comprising an EAF PEGylated blood protein into the subject prior to during or subsequent to the blood transfusion.
IN2089MUN2014 2012-03-20 2013-03-12 IN2014MN02089A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261613105P 2012-03-20 2012-03-20
PCT/US2013/030355 WO2013142135A1 (en) 2012-03-20 2013-03-12 Method of enhancing efficacy of blood transfusions

Publications (1)

Publication Number Publication Date
IN2014MN02089A true IN2014MN02089A (en) 2015-09-11

Family

ID=49223191

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2089MUN2014 IN2014MN02089A (en) 2012-03-20 2013-03-12

Country Status (10)

Country Link
US (2) US8859499B2 (en)
EP (1) EP2827887A4 (en)
JP (1) JP2015515462A (en)
BR (1) BR112014023200A2 (en)
CL (1) CL2014002464A1 (en)
HK (1) HK1204267A1 (en)
IN (1) IN2014MN02089A (en)
MX (1) MX2014011186A (en)
WO (1) WO2013142135A1 (en)
ZA (1) ZA201407616B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017120461A1 (en) 2016-01-08 2017-07-13 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
IN2014MN02089A (en) * 2012-03-20 2015-09-11 Einstein Coll Med
CA2933440A1 (en) 2013-12-09 2015-06-18 Saul A. VILLEDA Methods and compositions for treating aging-associated conditions
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
EP3218011A4 (en) * 2014-11-14 2018-06-27 Aima Biotech Conjugated proteins
AR102778A1 (en) 2014-11-25 2017-03-22 Nanobiotix PHARMACEUTICAL COMPOSITION, ITS PREPARATION AND ITS USES
EP3096160B1 (en) * 2015-05-20 2020-02-26 Veoneer Sweden AB An fmcw vehicle radar system
TW201705977A (en) 2015-05-28 2017-02-16 奈諾生技公司 Nanoparticles for use as a therapeutic vaccine
NZ738675A (en) 2015-06-15 2019-10-25 Univ Leland Stanford Junior Methods and compositions for treating aging-associated conditions
US11065277B2 (en) * 2015-11-09 2021-07-20 Albert Einstein College Of Medicine Method of ameliorating side effects of sickle cell disease treatments
WO2017103914A1 (en) * 2015-12-17 2017-06-22 Regentis Biomaterials Ltd. Ready for use organic solvent free compositions comprising protein-polymer conjugates and uses thereof
EP3995141B1 (en) 2016-04-28 2024-01-03 Alkahest, Inc. Plasma fractions as therapy for thymic cancer
US10525107B2 (en) 2016-08-18 2020-01-07 Alkahest, Inc. Blood plasma fractions as a treatment for aging-associated cognitive disorders
US11040068B2 (en) 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
MA48480A (en) 2017-04-26 2020-03-04 Alkahest Inc DOSAGE SCHEDULE FOR THE TREATMENT OF COGNITIVE AND MOTOR DEFICIENCIES WITH BLOOD PLASMA AND BLOOD PLASMA PRODUCTS
WO2019018403A1 (en) 2017-07-18 2019-01-24 Virtech Bio, Llc Blood substitutes comprising hemoglobin and methods of making
CN113056275B (en) 2018-10-26 2024-10-01 万能溶剂有限公司 Use of plasma and plasma fractions for improving pain, wound healing and postoperative recovery
JP2022129250A (en) * 2021-02-24 2022-09-05 学校法人 中央大学 Polyoxazoline-bound albumin, artificial plasma expander, and hemorrhagic shock resuscitation fluid

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267269A (en) * 1980-02-05 1981-05-12 Baxter Travenol Laboratories, Inc. Red cell storage solution
JPS56139419A (en) * 1980-03-31 1981-10-30 Kuraray Co Ltd Erythrocytic preservative and erythrocytic pharmaceutical for preservation
CA2320156A1 (en) * 1997-09-26 1999-04-08 Uab Research Foundation Reduced antigenic cells and uses therefor
DE69913716T2 (en) * 1998-09-25 2004-10-07 Oklahoma Med Res Found INHIBITION OF SICKENING OF ERYTHROCYTES BY N-L-ALPHA-ASPARTYL-L-PHENYL ALANINE 1-METHYL ESTER
US6251927B1 (en) * 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
US6875423B1 (en) * 1999-09-21 2005-04-05 Marcos Intaglietta Methods for increasing peripheral blood circulation
EP2292657A1 (en) * 1999-11-12 2011-03-09 Baxter Biotech Technology S.A.R.L. Reduced side-effect hemoglobin compositions
US6811778B2 (en) 2001-09-10 2004-11-02 Biopure Corporation Method for improving oxygen transport by stored red blood cells
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US7144989B2 (en) * 2002-03-25 2006-12-05 Albert Einstein College Of Medicine Of Yeshiva University Pegylated non-hypertensive hemoglobins, methods of preparing same, and uses thereof
US7521174B2 (en) * 2003-12-05 2009-04-21 Albert Einstein College Of Medicine Of Yeshiva University Universal red blood cells, methods of preparing same, and uses thereof
CA2588517A1 (en) * 2004-12-01 2006-06-08 Devgen N.V. 5-carboxamido substituted thiazole derivatives that interact with ion channels, in particular with ion channels from the kv family
WO2006135740A1 (en) * 2005-06-10 2006-12-21 Albert Einstein College Of Medicine Of Yeshiva University Pegylated hemoglobin and albumin and uses thereof
US8071546B2 (en) * 2005-06-10 2011-12-06 La Jolla Bioengineering Institute Uses of pegylated albumin
CA2749698C (en) * 2009-01-30 2017-08-01 Cuthbert O. Simpkins Resuscitation fluid
WO2010117423A2 (en) * 2009-03-31 2010-10-14 Duke University A METHOD FOR TREATING A PATIENT HAVING OR AT RISK FOR DEVELOPING A DISORDER ASSOCIATED WITH DECREASED EXPRESSION OF ß2 ADRENERGIC RECEPTORS OR NEED FOR INCREASED ß2 ADRENERGIC RECEPTOR ACTIVITY
PL2440239T3 (en) * 2009-06-09 2018-01-31 Prolong Pharmaceuticals Llc Hemoglobin compositions
US20110189166A1 (en) * 2010-01-29 2011-08-04 John Boucher Methods of treating hemorheologic abnormalities in mammals
WO2011106086A1 (en) * 2010-02-25 2011-09-01 Albert Einstein College Of Medicine Of Yeshiva University Pegylated albumin polymers and uses thereof
IN2014MN02089A (en) * 2012-03-20 2015-09-11 Einstein Coll Med
EP3218011A4 (en) 2014-11-14 2018-06-27 Aima Biotech Conjugated proteins

Also Published As

Publication number Publication date
CL2014002464A1 (en) 2015-08-28
EP2827887A4 (en) 2016-04-20
BR112014023200A2 (en) 2018-09-18
WO2013142135A1 (en) 2013-09-26
HK1204267A1 (en) 2015-11-13
US20130261061A1 (en) 2013-10-03
MX2014011186A (en) 2015-03-06
ZA201407616B (en) 2016-08-31
US8859499B2 (en) 2014-10-14
JP2015515462A (en) 2015-05-28
US20150017146A1 (en) 2015-01-15
US9498537B2 (en) 2016-11-22
EP2827887A1 (en) 2015-01-28

Similar Documents

Publication Publication Date Title
IN2014MN02089A (en)
HK1252481A1 (en) Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
MX2015002669A (en) Methods of administering pirfenidone therapy.
UA115231C2 (en) Imidazohyrrolidinone compounds
MX353482B (en) METHODS FOR THE TREATMENT OF CANCER and INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR.
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
EA201491773A1 (en) TREATMENT OF MULTIPLE SCLEROSIS BY COMBINATION OF LAKININIMODE AND DIMETYL FUMARATE
MY188139A (en) Sodium channel modulators for the treatment of pain
AP2014007533A0 (en) Substituted benzylindazoles for use as BUB1 kinaseinhibitors in the treatment of hyperproliferative diseases
EA201991014A1 (en) DIABETES TREATMENT
EA201491500A1 (en) FIBROZA TREATMENT METHODS
GB201207543D0 (en) Treatment of transfusion blood
PH12014502551B1 (en) Oligonucleotide chelate complex-polypeptide compositions and methods
EA201500370A1 (en) PHARMACEUTICAL COMBINATIONS CONTAINING DOUBLE ANGIOPOETIN-2 / Dll4 BINDING AGENTS AND ANTI-VEGF-R AGENTS
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
GB201022049D0 (en) Methods
IL239078A0 (en) Protein for use in the treatment of ocular diseases
MX362111B (en) A method of improving liver function.
WO2014005153A3 (en) Methods for treating mds1-evi1 mediated cancer
EA201492161A1 (en) N-METHYL-4-BENZYLKARBAMIDOPYRIDINE CHLORIDE AND METHOD FOR ITS PREPARATION
GB201206628D0 (en) Subcutaneous administration of PEGylated blood clotting factors
UA97741C2 (en) Method for regeneration of skin integuments in patients with deep burns by microautodermotransplants
UA79303U (en) use of taurine as agent for stabilizing the concentration in blood plasma in the treatment of fungal diseases
UA65038U (en) method for treatment of patients with tocomanias
UA71871U (en) Method for diagnostics of effectiveness of antibiotic therapy in patients with lime-boreliosis